Valeant's Goldman Connection: A CFO Schooled on Wall Street
- Schiller was key architect behind drug company's acquisitions
- He resigned after Allergan deal fell apart, remains on board
Valeant Walking Away From Embattled Philidor RX
This article is for subscribers only.
With an impeccable Wall Street pedigree -- 24 years at Goldman Sachs Group Inc., culminating in a top investment-banking job -- Howard Schiller left for what was fast becoming another palace of deal-making: Valeant Pharmaceuticals International Inc.
Schiller became a key architect of the drug company’s breathtaking rise and, it turns out, of its sudden decline. As Valeant’s chief financial officer, he helped build a deal machine that rewrote the rules of the pharmaceuticals industry. Along the way, he kept Wall Street close.